the company dilutes as needed to fund the company and they've been very frugal in their efforts compared to most bio's i follow.
last quarter was well above historical averages due to the # of trials being finalized. if you were to look at historical averages, the number ur hanging ur hat on would probably drop by half.
the number as presented is also a function of volume.